The fertility treatment clinic Iswarya has secured a funding round of 350 crore rupees from OrbiMed Asia. This move is notable as it is the first time in the organization's forty-year history that it has required external financing.
History of slow growth
Most fertility treatment chains expanding across India over the last decade have done so with venture capital support, which has fostered rapid and sometimes aggressive growth. Iswarya chose a different path. Founded in Chennai in 1986 by Dr. Chandralekha alongside co-founder Veluswamy, the organization developed gradually, being entirely self-funded for nearly forty years.
Today, the network includes over 85 centers in eight states, making it the largest service provider network in South India. During this period, it has helped more than 300,000 couples start families. Dr. Chandralekha, who continues to work as founder and chief clinical director, emphasizes the philosophy of this gradual growth: every opened center is guided by the conviction that clinical excellence and compassion must go hand in hand, rather than competing for accelerated expansion.
Significance of the current round
The current funding round takes on special significance against the backdrop of India's demographic indicators. According to the Government of India's Sample Registration System Statistical Report for 2024, the total fertility rate in India has dropped to 1.9, below the replacement level of 2.1 needed for long-term population stability.
Simultaneously, the increasing number of couples needing fertility treatment due to delayed parenthood, lifestyle issues, and improved diagnostic capabilities means that more couples than ever require such treatment, despite IVF penetration in India remaining one of the lowest in the world. It is this gap between growing need and limited access that represents an opportunity upon which Iswarya and now OrbiMed are betting.
Development strategy with OrbiMed
Iswarya's Managing Director, Dr. Arun Muthuvel, defined the next phase of the company precisely around this gap: deepening presence in existing markets, reaching underserved geographical areas ignored by larger chains, and continuously raising standards of clinical outcomes instead of simply accelerating center openings compared to competitors.
OrbiMed's investment and its goals
For OrbiMed, an investment firm managing approximately $18 billion in assets globally and historically focused on biopharmaceuticals, medical devices, and diagnostics, this represents a targeted expansion into fertility treatment. In a joint statement, Sunny Sharma and Arun Sadhanandham from OrbiMed noted that forty years of disciplined development without external capital allowed them to build strong clinical results, a reliable brand, and a capital-efficient operating model. Essentially, it is a business that has already proven its viability before starting to attract external funds for scaling up.
The capital raised will be directed towards opening new centers in underprivileged regions, strengthening clinical infrastructure, developing digital capabilities, and expanding Iswarya's embryology talent pool—a specialized skill base that is often a real bottleneck when responsibly scaling fertility treatment services.
The significance of Iswarya's history
Iswarya's funding round is not so much a story about a hot startup attracting investor attention. Rather, it is the reverse situation: a medical institution that spent forty years proving the viability of its model without external capital, patiently, one center and one family at a time, before needing to seek support. In an industry where 'growth at any cost' mentality often dominates, Iswarya's journey serves as a reminder that sometimes the most valuable enterprises are those that waited the longest before asking for funding.